




FIG. 1




Fig. 2

CDR L2

CDR L3

50	60	70	80	90	100																																																			
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	F	Y	S	L	T	I	S	S	V	E	A	E	D	A	A	D	Y	F	C	H	Q	W	S	T	Y	H	T	F	G	S	G	T	K	L	E	I	K
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	F	Y	S	L	T	I	S	S	V	E	A	E	D	A	A	D	Y	F	C	H	Q	W	S	T	Y	H	T	F	G	S	G	T	K	L	E	I	K
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	F	Y	S	L	T	I	S	S	V	E	A	E	D	A	A	D	Y	F	C	H	Q	W	S	T	Y	H	T	F	G	S	G	T	K	L	E	I	K
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	F	Y	S	L	T	I	S	S	V	E	A	E	D	A	A	D	Y	F	C	H	Q	W	S	T	Y	H	T	F	G	S	G	T	K	L	E	I	K
Y	T	S	N	L	A	S	G	V	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	K	I	S	R	V	E	A	E	D	V	G	V	Y	Y	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K	
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	E	F	T	L	T	I	S	S	L	Q	P	D	D	F	A	T	Y	Y	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K	
Y	T	S	N	L	A	S	G	I	P	P	R	F	S	G	S	G	Y	G	T	D	F	T	L	T	I	N	I	E	S	E	D	A	A	Y	F	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K			
Y	T	S	N	L	A	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K	
Y	T	S	K	L	A	S	G	V	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	K	I	S	R	V	E	A	E	D	V	G	V	Y	Y	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K	
Y	T	S	S	L	A	S	G	V	P	D	R	F	S	G	S	G	S	G	T	D	F	T	L	K	I	S	R	V	E	A	E	D	V	G	V	Y	Y	C	H	Q	W	S	T	Y	H	T	F	G	Q	T	K	V	E	I	K	

FIG. 3




FIG. 4




FIG. 5A

5/60




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6A

7/60




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 7A




FIG. 7B




FIG. 7C

10/60




FIG. 8A

11/60




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D

14/60




FIG. 9E




FIG.10




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D

18/60




FIG. 11E




FIG. 12




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22A

34/60




FIG. 22B




FIG. 23A




FIG. 23B




FIG. 24A




FIG. 24B




FIG. 24C




FIG. 25A




FIG. 25B




FIG. 25C




FIG. 26A




FIG. 26B




FIG. 26C




FIG. 27A

41/60




Fig. 27B

42/60




Fig. 27C

tumor microenvironment pH




FIG. 28A




FIG. 28B

45/60




FIG. 29A

46/60




FIG. 29B




FIG. 29C




FIG. 30A




FIG. 30B




FIG. 30C




FIG. 30D




FIG. 30E




Fig. 31A




Fig. 31B




Fig. 31C




Fig. 31D




Fig. 31E




FIG. 32A




FIG. 32B





FIG. 33



EXPECTED CLOSING IN NON-HUMAN PRIMATES <0.25mg/kg w/ CURRENT CABs

FIG. 34

NON-HUMAN PRIMATES
WT-EPCAM x WT-CD3
0.25mg/kg = 2 EXPIRED
0.05mg/kg = 1 EXPIRED; 1 ILL (RECOVERED)
0.025mg/kg = 2 ILL (RECOVERED)

GI AND KIDNEY FUNCTION WAS IMPACTED.
MARKED INCREASE IN ALP, ALT, AST, TBIL, CK
WERE NOTED IN THESE ANIMALS.
HEPATOCELLULAR AND CHOLESTATIC INJURY WAS
IDENTIFIED BASED ON THE CURRENT CLIN PATH DATA

NON-HUMAN PRIMATES
WT-EPCAM x WT-CD3
0.25mg/kg = 1 HEALTHY; 1 ILL (RECOVERED)
0.05mg/kg = 2 HEALTHY
0.025mg/kg = 2 NORMAL

AT HIGH DOSE SEE SOME EARLY SIGNS OF
TOXICITY
NO TOXICITY OBSERVED AT THE LOWER DOSES

[illegible][illegible]

	210	220	230	240	250	260
huEpCAM-ECD	QNDVDIAD	VAAYFEKDDVK	GESLFS~KKMDLT	YNGEQLDLP	GQTILYYV	DEKAFESMQGLK
cytoEpCAM-ECD				R		
ch1EpCAM-HIS						SRHHHHHHHHH
ch2EpCAM-HIS						SRHHHHHHHHH
ch3EpCAM-HIS	D					SRHHHHHHHHH
ch4EpCAM-HIS	D	S	S	R	P	~SRHHHHHHHHH
himepCAM-ECD	D	S	S	R	P	~




Fig. 36

	30	40	50	60
	 x			
huEpCAM	QEECV	CENYKLA	VNCFVNNNRQCQCTSVGAQNTVICSKLA	
cynoEpCAM	.	.	L.D.G.	I.L.
chlEpCAM	RD.	D.	TS.SL.EYGE.	Y.T.
huEpCAM-M1	RD.	.	.	.
huEpCAM-M2	.	TS.	.	.
huEpCAM-M3	.	.	Y.	.
huEpCAM-M4	RD.	TS.	.	.
huEpCAM-M5	.	TS.	Y.	.
huEpCAM-M6	RD.	.	Y.	.
huEpCAM-M7	RD.	TS.	Y.	.

Fig. 37




Fig. 38




Fig. 39